<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02073812</url>
  </required_header>
  <id_info>
    <org_study_id>Rempex 503</org_study_id>
    <nct_id>NCT02073812</nct_id>
  </id_info>
  <brief_title>Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RPX7009(beta-lactamase inhibitor) is being studied in combination with a carbapenem (RPX2014)&#xD;
      to treat bacterial infections, including those due to multi-drug resistant bacteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The worldwide spread of resistance to antibiotics among Gram-negative bacteria, particularly&#xD;
      members of the ESKAPE group of pathogens, has resulted in a crisis in the treatment of&#xD;
      hospital acquired infections. In particular, the recent dissemination of a serine&#xD;
      carbapenemase (e.g., KPC) in Enterobacteriaceae in US hospitals now poses a considerable&#xD;
      threat to the carbapenems and other members of the beta-lactam class of antimicrobial agents.&#xD;
&#xD;
      Rempex is developing a fixed combination antibiotic of a carbapenem (RPX2014) plus a new&#xD;
      beta-lactamase inhibitor (RPX7009) which has activity against serine beta-lactamases,&#xD;
      including KPC. This Phase 1 study will assess the pharmacokinetics of intravenous RPX2014 and&#xD;
      RPX7009 in plasma and epithelial fluid.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics from baseline through the end of the study</measure>
    <time_frame>2 days</time_frame>
    <description>Assessment of plasma, ELF and AM concentrations of RPX2014 and RPX7009 after 3 doses of Carbavance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IV Carbavance concentrations in lung fluid</measure>
    <time_frame>2 days</time_frame>
    <description>Plasma, ELF and AM concentrations of intravenous Carbavance in healthy adult subjects.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Multiple dose of Carbavance (RPX7009/RPX2014)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose of Carbavance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPX7009 and RPX2014</intervention_name>
    <description>The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)</description>
    <arm_group_label>Multiple dose of Carbavance (RPX7009/RPX2014)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult males and/or females, 18 to 55 years of age (inclusive) at the time of&#xD;
             screening.&#xD;
&#xD;
          2. Body mass index (BMI) ≥ 18.5 and ≤ 30 (kg/m2) and weight between 55.0 and 100.0 kg&#xD;
             (inclusive) at the time of screening.&#xD;
&#xD;
          3. Medically healthy with clinically insignificant screening results (e.g., laboratory&#xD;
             profiles, medical histories, electrocardiograms (ECGs), physical examination) as&#xD;
             deemed by the PI.&#xD;
&#xD;
          4. Non-tobacco/nicotine-containing product users for a minimum of 6 months prior to Day&#xD;
             1.&#xD;
&#xD;
          5. Voluntarily consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of significant oncologic, cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             neurological, or psychiatric disease.&#xD;
&#xD;
          2. Positive urine drug/alcohol testing at screening (or Day -1).&#xD;
&#xD;
          3. Positive testing for human immunodeficiency virus (HIV) or hepatitis B surface antigen&#xD;
             (HBsAg).&#xD;
&#xD;
          4. History or presence of alcoholism or drug abuse within the 2 years prior to Day 1.&#xD;
&#xD;
          5. Hypersensitivity or idiosyncratic reaction to beta-lactam antibiotics (e.g.&#xD;
             penicillins, cephalosporins, carbapenems, etc.).&#xD;
&#xD;
          6. Clinically significant pulmonary or any other disease that prevents a subject from&#xD;
             undergoing bronchoscopy with bronchopulmonary lavage.&#xD;
&#xD;
          7. History of seizures (e.g., epilepsy), head injury or meningitis requiring ongoing&#xD;
             anti-seizure medications.&#xD;
&#xD;
          8. Use of any prescription medication (with the exception of hormonal contraceptives or&#xD;
             hormone replacement therapy for females) within 14 days prior to Day 1.&#xD;
&#xD;
          9. Participation in another investigational clinical trial within 30 days prior to Day 1.&#xD;
&#xD;
         10. Females who are pregnant or lactating.&#xD;
&#xD;
         11. Surgery within the past three months prior to Day 1 determined by the PI to be&#xD;
             clinically relevant.&#xD;
&#xD;
         12. Any acute illness including clinically significant infection within 30 days prior to&#xD;
             Day 1.&#xD;
&#xD;
         13. QTcF interval &gt;450 msec, or history of prolonged QT syndrome at screening (or Day 1).&#xD;
&#xD;
         14. Calculated creatinine clearance less than 80 mL/min (Cockroft-Gault method) at&#xD;
             screening.&#xD;
&#xD;
         15. Subjects who have any clinically significant abnormalities on laboratory values at&#xD;
             screening (or Day -1), including:&#xD;
&#xD;
               1. White blood cell count (WBC) &lt; 3,000/mm3, hemoglobin &lt; 11g/dL.&#xD;
&#xD;
               2. Absolute neutrophil count &lt; 1,200/mm3 or platelet count &lt; 120,000/mm3.&#xD;
&#xD;
         16. Liver function abnormalities at screening (or Day -1) (defined by an elevation in&#xD;
             bilirubin, AST or ALT 1.5 x ULN of the normal range for subjects based on age and&#xD;
             sex).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Gotfried, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pulmonary Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2014</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

